Last reviewed · How we verify
veverimer daily
veverimer daily is a Small molecule drug developed by Tufts Medical Center. It is currently in Phase 1 development.
Veverimer is a small molecule that acts as a hydrochloric acid sequestering agent. It is being studied in clinical trials for conditions such as metabolic acidosis, osteopenia, and acidosis.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | veverimer daily |
|---|---|
| Sponsor | Tufts Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia (PHASE1)
- Long-term Safety Extension to Study TRCA-301 (PHASE3)
- Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease (PHASE3)
- Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- veverimer daily CI brief — competitive landscape report
- veverimer daily updates RSS · CI watch RSS
- Tufts Medical Center portfolio CI
Frequently asked questions about veverimer daily
What is veverimer daily?
Who makes veverimer daily?
What development phase is veverimer daily in?
Related
- Manufacturer: Tufts Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing